Ventripoint Diagnostics Ltd. has reached another development milestone by submitting its next generation of software, VMS+4.0, to the U.S. Food and Drug Administration ("FDA"). This latest advance of Ventripoint's AI-powered technology, which rapidly processes ultrasound images of the heart to generate MRI-quality measurements of all four cardiac chambers, will seamlessly integrate into the workflow of hospitals, clinics and caregivers. The advances achieved by VMS+4.0 means Ventripoint's heart-scanning technology will now offer: Novel presentation of full cardiac motion of all four 3D reconstructed chambers of the heart through the cardiac cycle.

Automated plotting of key anatomical landmarks of the heart, removing the need for manual inputs and providing greater confidence in the analysis. This provides greater reliability, consistency and reproducibility of the volumetric measurements. Increased analysis speed, making heart images available in minutes, not the hours needed for MRI imaging.

Full-scope use - meaning newborns to adults can be easily scanned and assessed. Magnet-free sensors, reducing procedure time by eliminating a calibration procedure. Interfaced with any ultrasound machine within minutes.

Enhanced visualization tools including strain and heat maps. Breakthrough vector-motion technology to show the wall movement of the different chambers of the heart. This provides a novel and unique way of visualizing the motion of the heart including twist.

Ventripoint submitted VMS+4.0 for clearance by FDA on May 1, a requirement for significant software and hardware updates and diagnostic advances. The company are also pursuing regulatory clearance in other key markets such as the E.U., U.K and Canada to make this newest version of Ventripoint available to the global community.